Pharmacometabolomic of Trabectedin in Soft Tissue Patients

CompletedOBSERVATIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Sarcoma
Interventions
DRUG

Trabectedin

1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.

All Listed Sponsors
lead

Centro di Riferimento Oncologico - Aviano

OTHER

NCT04394728 - Pharmacometabolomic of Trabectedin in Soft Tissue Patients | Biotech Hunter | Biotech Hunter